The rising cases of chronic obstructive pulmonary diseases (COPDs), diabetes, cancer, and cardiovascular diseases (CVDs) have amplified the adoption of minimally invasive blood-drawing devices such as lancets. According to the World Health Organization (WHO), currently nearly 235 million people are suffering from asthma and around 3 million individuals die due to COPDs each year. The organization also states that cancer kills around 9.6 million people and heart diseases claim 17.9 million human lives each year. Medical professionals use lancets to diagnose such diseases at their early stages to reduce the mortality rate.
Additionally, the escalating adoption of such medical devices in homecare settings will fuel the lancet industry at a CAGR of 9.5% during 2020–2030. The market generated $830.3 million revenue in 2019. Lancets made for homecare settings are easier to utilize than those applied in hospitals and clinics. Owing to their easy availability and usage, the devices are gaining wide popularity among the geriatric population, especially among diabetic patients.
 |
| Get the sample pages of this report: https://bit.ly/43I91lO |
Market players are providing simple, point-of-care-testing (POCT), home-use lancets for monitoring blood glucose, diagnosing diabetes, and other purposes. OneTouch UltraSoft by LifeScan Inc. is one of the most widely used lancets in homecare settings. With the rising incidence of diabetes, adoption of such devices will surge significantly. The WHO estimates that nearly 1.6 million people die of diabetes each year and about 422 million people are currently affected by this endocrine disease, globally. Diabetic patients use lancets to monitor units of insulin being administered, as its regulation is quintessential for such people.
The type segment of the lancet market is bifurcated into safety and standard. Under this segment, the safety category held larger market share in 2019, as safety lancets are meant for single use that reduces the risk of contracting an infection. These lancets are created to retract automatically after pricking the skin, thereby, preventing injuries and minimizing the risk of accidental pricks. These instruments are used to prick the capillary without using a lancing device. Owing to such properties, the category will demonstrate higher growth in the forecast period.
In recent years, major market players have started entering into distribution agreements with smaller firms to magnify their sales in regions beyond their direct sales channels' reach. For instance, Owen Mumford Ltd. signed an agreement with NIPRO Corporation, in July 2019. The former aims to increase the distribution channel of UniSafe springless devices in Japan through the latter, which is an Osaka-based firm. Other players following the same footprint include F. Hoffmann-La Roche Ltd., B. Braun Melsungen AG, and HTL-STREFA S.A.
According to P&S Intelligence, North America adopted the highest number of lancets in 2019, due to the rising prevalence of chronic diseases, surging population of elderly people, and increasing technological advancements, in the region. According to the Center for Disease Control and Prevention (CDC), in the U.S., more than 34 million individuals are living with diabetes. The CDC also states that nearly 600,000 deaths in the country occur due to cancer and approximately 1.7 million cases are registered every year.
Whereas, the Asia-Pacific lancet market will exhibit the fastest growth during the forecast period. This can be ascribed to the improving healthcare infrastructure, booming elderly population, magnifying purchasing power, rising prevalence of chronic ailments, and increasing number of initiatives by public and private organizations to spread awareness regarding diabetes. The United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) propounds that by 2050, one in four people in the region will be over 60 years old. Further, the WHO states that around 6 million people in Southeast Asia have diabetes.
Thus, the increasing preference for minimally invasive procedures and the booming number of diabetic patients will propel the usage of lancets in the coming years.
No comments:
Post a Comment